Navigation Links
Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions
Date:4/7/2011

ncrease of levodopa and monitor haloperidol patients for worsening of schizophrenic symptoms and development of dyskinesia.

The anticholinergic effects of CUVPOSA™ may be increased with concomitant administration of amantadine. CUVPOSA™ dose reduction should be considered.

Use with caution in patients with renal impairment.

The most common adverse reactions (incidence greater than or equal to 30%) are dry mouth (40%), vomiting (40%) constipation (35%), flushing (30%), and nasal congestion (30%).

For full prescribing information, please visit www.CUVPOSA.com.  

To report SUSPECTED ADVERSE REACTIONS, contact Shionogi Pharma, Inc. at 1-800-849-9707 ext. 1454 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About Shionogi & Co., Ltd.

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients.  Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and Doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp.  For more information on Shionogi Inc., headquartered in Florham Park, NJ, please visit www.shionogi-inc.com.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently availa
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
2. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
3. Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
6. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
7. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
8. Mtech Announces Finalists for University of Maryland $75K Business Plan Competition
9. Caliper Life Sciences Announces Date and Location of its 2011 Annual Meeting of Stockholders
10. Kimberly-Clark Health Care Announces Strategic Green Partnerships, Commitment to Reducing Medical Waste
11. Dendreon Announces Presentation of Data at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... OAKS, Calif., April 21, 2015 Amgen (NASDAQ: ... first quarter of 2015. Key results include: , ... of 2014 to $5,033 million, with 12 percent product ... Prolia ® (denosumab), EPOGEN ® (epoetin alfa), ... Unfavorable changes in foreign exchange rates impacted total revenue ...
(Date:4/21/2015)... , 21. April 2015  CorTechs Labs, ... quantitative Analyse des Hirnvolumens freut sich, eine ... Pharmaunternehmen, bekannt geben zu können. Die Unternehmen ... des Hirnvolumens zusammenarbeiten, der die Identifizierung, Messung ... Patienten mit multipler Sklerose als Ziel hat. ...
(Date:4/21/2015)... -- Lincoln Computer Services has taken a proactive approach to ... LCS donated 10 laptops and carts to the Good ... Home at Riverdale by RiverSpring ... is a creative, non-pharmacological approach to Alzheimer,s care that ... in the morning, start their day off in a ...
Breaking Medicine Technology:Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 3Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 5Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 6Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 7Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 8Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 9Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 10Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 11Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 12Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 13Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 14Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 15Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 16Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 17Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 18Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 19CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2Lincoln Continues Support of the Community: Donates 10 Laptops for Alzheimer's Program 2
... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will present updated results from its,Phase 2 ... a,poster discussion session at the International Association for ... on Lung Cancer in Seoul, Korea.,Details follow: ...
... - Positive Phase 2 Clinical Trial Results from PI-88 in ... $92.4 million in Raised Capital Highlight the Year ... PGL; Nasdaq: PGLA) today released its,financial results for the fiscal ... * Announced positive results from a Phase 2, 172 ...
Cached Medicine Technology:Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 2Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 3Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 2Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 3
(Date:4/21/2015)... April 21, 2015 Displays & Exhibits, ... in the trade show exhibit building industry, announced a ... sales offices of Absolute Exhibits in Tustin, California.“It is ... shoppers to observe the variation in quality as offered ... Exhibits,” explained Zenos Adduru. Mr. Adduru is the new ...
(Date:4/21/2015)... San Francisco, CA and Orlando, FL (PRWEB) April ... for Behavioral Health (National Council) will honor Dina ... Support Services for PREP (Prevention and Recovery in ... the National Council Award of Excellence: Peer Specialist ... NatCon15 awards ceremony, known as the Oscars of ...
(Date:4/21/2015)... Henry Mayo Newhall Hospital, located in ... to automatically send continuation of care documents (CCDs). ... improve communication with clinics and other ambulatory practices, they ... solution. , “Provider Alert will enable the physician ... they need to provide continuing care in real time,” ...
(Date:4/21/2015)... April 21, 2015 Grafika is pleased ... printer, Offset Impressions. , “We’re excited about ... of printing capabilities and knowledgeable team members,” according to ... allows us to offer an ever wider breadth of ... packaging, and specialty services we already offer. It ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 2Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 3Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 4Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... losing in a way that's making other communities in the ... a town of 80,000 outside Boston, have been taking part ... eating habits that stay with them throughout their lives. As ... those in nearby towns, and as they learn to eat ...
... felt on the world fashion map, it is attracting ... the ramp here but also try their luck in ... matured as designers stopped copying Western motifs blindly. India ... as becoming a profitable business destination for international buyers. ...
... functions may be vulnerable to Alzheimers disease if they ... blood vessels in the brain, says a study ... in the Journal of Neuroimaging, also suggests that people ... the disease than their peers. ,Alzheimers ...
... Elevated CO2 is considered to be a serious catalyst ... the ecosystem , including the insect-plant food chain link.Safeguarding ... and national economies. ,In research to be presented ... Plant Biologists in Chicago (July 7-11, 2007), scientists will ...
... who received the world's first face transplant 18 months ago said ... herself in the mirror with a combination of sadness and wonder. ... who have a face, a smile, facial expressions which allow them ... in an interview published in Saturday's edition of Le Monde. ...
... Africa on Friday after they came into contact with an ... ,Inspector Juanita Kilian said police had received a complaint ... of Johannesburg, about a "suspicious" envelope, she told public radio. ... this stage we cannot confirm that the contents were anthrax," ...
Cached Medicine News:Health News:Somerville, A Town Committed to Tackle Obesity Among Kids 2Health News:Somerville, A Town Committed to Tackle Obesity Among Kids 3Health News:Indian Fashion Beckons International Models 2Health News:Elevated Carbondioxide may Have Negative Impact on Ecosystem 2Health News:World's First Face Transplant Patient Feels She is Alive Again 2
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... Digisonics has set the standard in ... review station, the only fully integrated ... multi-modality reporting., ,DigiView cardiology solutions bring ... professional reporting choices, an integrated clinical ...
... The menu-driven Vapro osmometer determines osmolality ... natural equilibrium. ,What you don't get are ... particles, or other conditions that interfere with ... percent in the clinical range) Vapro osmometer ...
Medicine Products: